Lantheus Inc. (LNTH)
| Bid | 104.08 |
| Market Cap | 7.4B |
| Revenue (ttm) | 1.53B |
| Net Income (ttm) | 312.44M |
| EPS (ttm) | 4.36 |
| PE Ratio (ttm) | 24.78 |
| Forward PE | 13.41 |
| Analyst | Buy |
| Ask | 110 |
| Volume | 430,312 |
| Avg. Volume (20D) | 903,298 |
| Open | 108.37 |
| Previous Close | 108.74 |
| Day's Range | 106.93 - 108.59 |
| 52-Week Range | 74.28 - 126.89 |
| Beta | 0.20 |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brai...
Analyst Forecast
According to 6 analyst ratings, the average rating for LNTH stock is "Buy." The 12-month stock price forecast is $127, which is an increase of 17.56% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent ExpiryLantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, includin...
